PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBrimonidine
Alphagan, Mirvaso(brimonidine)
Alphagan P, Brimonidine, Combigan, Lumify, Mirvaso, Qoliana, Simbrinza (brimonidine) is a small molecule pharmaceutical. Brimonidine was first approved as Alphagan on 1996-09-06. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension, open-angle glaucoma, and skin diseases. The pharmaceutical is active against alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor.
Download report
Favorite
Novartis Pharmaceuticals
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Alphagan p, Brimonidine, Lumify, Mirvaso, Qoliana (discontinued: Alphagan, Brimonidine)
Combinations
Brimonidine timolol, Combigan, Simbrinza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brimonidine tartrate
Tradename
Company
Number
Date
Products
ALPHAGAN PAbbVieN-021770 RX2005-08-19
1 products, RLD, RS
ALPHAGAN PAbbVieN-021262 RX2001-03-16
1 products, RLD, RS
LUMIFYBausch Health CompaniesN-208144 OTC2017-12-22
1 products, RLD, RS
LUMIFY PRESERVATIVE FREEBausch Health CompaniesN-218424 OTC2024-04-19
1 products, RLD, RS
MIRVASOGaldermaN-204708 RX2013-08-23
1 products, RLD, RS
QOLIANASandozN-021764 RX2006-05-22
1 products, RLD, RS
Show 2 discontinued
Brimonidine tartrate
+
Timolol maleate
Tradename
Company
Number
Date
Products
COMBIGANAbbVieN-021398 RX2007-10-30
1 products, RLD, RS
Brimonidine tartrate
+
Brinzolamide
Tradename
Company
Number
Date
Products
SIMBRINZAAlcon ResearchN-204251 RX2013-04-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
alphagan pNew Drug Application2024-06-27
brim-dor pfunapproved drug other2018-05-08
brimonidineANDA2023-06-30
brimonidine tartrateANDA2024-09-19
brimonidine tartrate 0.25% / ivermectin 1% / metronidazole 1% / niacinamide 4%unapproved drug other2019-05-15
brimonidine tartrate 0.25% / potassium azeloyl diglycinate 8%unapproved drug other2019-05-15
brimonidine tartrate and timolol maleateANDA2024-11-08
brimonidine tartrate ophthalmic solution, 0.15%ANDA2023-07-06
brimonidine tartrate/timolol maleateANDA2024-05-16
brimonidine tartrate/timolol maleate ophthalmic solutionANDA2024-10-04
Show 6 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
heart failureHP_0001635D006333I50
hypertensionEFO_0000537D006973I10
myocardial infarctionEFO_0000612D009203I21
angina pectorisEFO_0003913D000787I20
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Brimonidine Tartrate, Mirvaso, Galderma Labs Lp
80534272031-06-13DPU-1428
81637252031-06-13DP
102015172031-06-13DP
85132472031-03-25DPU-1428
85132492031-03-25DPU-1428
98616312031-03-25U-1428
98616322031-03-25U-1428
74392412025-08-25U-1428
82318852025-05-24DP
84101022025-05-24U-1428
84264102025-05-24U-1428
88595512024-05-25U-1428
Brimonidine Tartrate / Brinzolamide, Simbrinza, Alcon Labs Inc
90444842030-10-30DP
94212652030-06-17DP
Brimonidine Tartrate, Lumify, Bausch And Lomb Inc
82937422030-07-14U-2222
92594252030-07-14U-2222
115966002029-07-27U-2222
118332452029-07-27U-2222
Brimonidine Tartrate, Qoliana, Sandoz
72651172025-08-19DP
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX21: Brimonidine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EA: Sympathomimetics in glaucoma therapy
— S01EA05: Brimonidine
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA07: Brimonidine
HCPCS
No data
Clinical
Clinical Trials
200 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008———1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Toxic optic neuropathyD000081028—H46.3—1———1
Ovarian epithelial carcinomaD000077216———1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBrimonidine
INNbrimonidine
Description
Brimonidine is a quinoxaline derivative, a secondary amine and a member of imidazoles. It has a role as an adrenergic agonist, an antihypertensive agent and an alpha-adrenergic agonist.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Brc1c(NC2=NCCN2)ccc2nccnc12
Identifiers
PDB—
CAS-ID59803-98-4
RxCUI—
ChEMBL IDCHEMBL844
ChEBI ID3175
PubChem CID2435
DrugBankDB00484
UNII IDE6GNX3HHTE (ChemIDplus, GSRS)
Target
Agency Approved
ADRA2B
ADRA2B
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
151
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Q9BZK0
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Brimonidine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Brimonidine
+
Timolol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,378 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
19,026 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use